RESULTS	M1 demonstrated that the initial increase in patient-reported fatigue with sunitinib was worst during cycle 1 , with mean values numerically better at subsequent cycles ; most pairwise comparisons of consecutive CTCAE fatigue cycle means were not found to be statistically significant .\